Millicent Pr Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MILLICENT PR, and what generic and branded alternatives to MILLICENT PR drugs are available?
MILLICENT PR has one approved drug.
Summary for Millicent Pr
| US Patents: | 0 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Millicent Pr
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Millicent Pr | FEMLYV | ethinyl estradiol; norethindrone acetate | TABLET, ORALLY DISINTEGRATING;ORAL | 218718-001 | Jul 22, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
